These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30320163)

  • 21. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
    Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
    PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton Pump Inhibitors and Dementia: Deciphering the Data.
    Moayyedi P; Lewis MA
    Am J Gastroenterol; 2017 Dec; 112(12):1809-1811. PubMed ID: 29215629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study.
    Sattayalertyanyong O; Thitilertdecha P; Auesomwang C
    Int J Clin Pharm; 2020 Feb; 42(1):174-183. PubMed ID: 31865594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinicopathological characteristics of gastric polyps and the relationship between fundic gland polyps, Helicobacter pylori infection, and proton pump inhibitors.
    Gao W; Huang Y; Lu S; Li C
    Ann Palliat Med; 2021 Feb; 10(2):2108-2114. PubMed ID: 33725768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GASTRIC FUNDIC GLAND POLYPS: CAN HISTOLOGY BE USEFUL TO PREDICT PROTON PUMP INHIBITORS USE?
    Brito HLF; Barros C; Freire MV; Silva Filho MND; Nascimento TV
    Arq Gastroenterol; 2018; 55(4):380-384. PubMed ID: 30785522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proton pump inhibitors and infection risk].
    Palencia-Herrejón E; Sánchez B; Escobar I; Gómez-Lus ML
    Rev Esp Quimioter; 2011 Mar; 24(1):4-12. PubMed ID: 21412664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.
    Martin FC; Chenevix-Trench G; Yeomans ND
    Aliment Pharmacol Ther; 2016 Nov; 44(9):915-925. PubMed ID: 27634363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites.
    Siple JF; Morey JM; Gutman TE; Weinberg KL; Collins PD
    Ann Pharmacother; 2012 Oct; 46(10):1413-8. PubMed ID: 23032651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: the long-term use of proton-pump inhibitors.
    Raghunath AS; O'Morain C; McLoughlin RC
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():55-63. PubMed ID: 16042660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Proton pump inhibitor-induced nephrotoxicity].
    Klatte DCF; Wiegersma JS; Dekker FW; Gansevoort RT
    Ned Tijdschr Geneeskd; 2021 Sep; 165():. PubMed ID: 34523835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis.
    Tergast TL; Wranke A; Laser H; Gerbel S; Manns MP; Cornberg M; Maasoumy B
    Liver Int; 2018 Sep; 38(9):1602-1613. PubMed ID: 29675988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indications and safety of proton pump inhibitor drug use in patients with cancer.
    Triadafilopoulos G; Roorda AK; Akiyama J
    Expert Opin Drug Saf; 2013 Sep; 12(5):659-72. PubMed ID: 23647006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
    Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton Pump Inhibitors: What the Internist Needs to Know.
    Spechler SJ
    Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms.
    Corsonello A; Lattanzio F; Bustacchini S; Garasto S; Cozza A; Schepisi R; Lenci F; Luciani F; Maggio MG; Ticinesi A; Butto V; Tagliaferri S; Corica F
    Curr Drug Metab; 2018; 19(2):142-154. PubMed ID: 29219052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients.
    Al-Tureihi FI; Hassoun A; Wolf-Klein G; Isenberg H
    J Am Med Dir Assoc; 2005; 6(2):105-8. PubMed ID: 15871884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton pump inhibitors--uncommon adverse effects.
    Oh S
    Aust Fam Physician; 2011 Sep; 40(9):705-8. PubMed ID: 21894279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report.
    Perry TW
    J Med Case Rep; 2021 Jul; 15(1):360. PubMed ID: 34301322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.
    Schnoll-Sussman F; Katz PO
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):1-9. PubMed ID: 28130652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential adverse effects of proton pump inhibitors.
    Coté GA; Howden CW
    Curr Gastroenterol Rep; 2008 Jun; 10(3):208-14. PubMed ID: 18625128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.